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ARTICLES

Bone Marrow Failure
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ABSTRACT

Inherited bone marrow failure syndromes are a group of rare, heterogeneous genetic disorders with a risk of clonal and malignant myeloid transformation including clonal marrow cytogenetic abnormalities, myelodysplastic
syndrome and acute myeloid leukemia. The clinical characteristics, risk classification, prognostic factors and outcome of clonal and malignant myeloid transformation associated with inherited bone marrow failure syndromes
are largely unknown. The aims of this study were to determine the impact of category, cytopathology and cytogenetics, the three components of the “Category Cytology Cytogenetics” classification of pediatric myelodysplastic syndrome, on the outcome of clonal and malignant myeloid transformation associated with inherited
bone marrow failure. We used data from the Canadian Inherited Marrow Failure Registry. Among 327 patients
with inherited bone marrow failure syndrome enrolled in the registry, the estimated risk of clonal and malignant
myeloid transformation by the age of 18 years was 37%. The risk of clonal and malignant myeloid transformation varied according to the type of inherited bone marrow failure syndrome but was highest in Fanconi anemia.
The development of clonal and malignant myeloid transformation significantly affected overall survival.
Mortality varied based on cytopathological group. The largest group of patients had refractory cytopenia. Clonal
marrow cytogenetic abnormalities were identified in 87% of patients with clonal and malignant myeloid transformation, and different cytogenetic groups had different impacts on disease progression. We conclude that category, cytopathology and cytogenetics in cases of clonal and malignant myeloid transformation associated with
inherited bone marrow failure syndromes have an important impact on outcome and that the classification of
such cases should incorporate these factors.

Introduction
Inherited bone marrow failure syndromes (IBMFS) are a
group of rare genetic disorders with single or multi-lineage
cytopenia resulting from impaired hematopoiesis and a variable degree of predisposition to cancer. These disorders carry
a risk of clonal and malignant myeloid transformation
(CMMT), which includes isolated clonal marrow cytogenetic
abnormalities (CMCA), myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML).1-8 There are multiple
reports of cases of IBMFS with early CMMT changes that
eventually progressed to either severe bone marrow failure,
advanced MDS and/or AML.9,10

The precise definition of adult and pediatric de novo CMMT
is still evolving, but it is widely accepted that it should be
based on peripheral blood cell numbers and types, and on
bone marrow blasts, cellularity, cytogenetics and presence of
dysplasia. Unfortunately, there is no widely accepted definition of IBMFS-associated CMMT.11 For example, Hasle et al.
defined pediatric MDS based on peripheral blood counts,
marrow morphologic dysplasia, CMCA and blasts.12 These
are measurable criteria and potentially excellent tools for
defining MDS. However, the ability of these criteria to
include all cases of IBMFS-associated MDS without falsely
including cases without true transformation has never been
tested.
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Apart from challenges in defining IBMFS-associated
CMMT, the classification and grading of this disorder
presents another challenge, because some of the clinical
and biological features that are used to characterize de novo
CMMT (e.g. prominent dysplasia and increased marrow
cellularity) are less common in IBMFS-associated CMMT.
In 2002 we developed the “Category Cytology
Cytogenetics” (CCC) classification for pediatric MDS,
which aimed to address aspects not only of de novo MDS,
but also of therapy-related and IBMFS-associated MDS.11
In the present study we examined the three components
of the CCC classification in a large cohort of patients with
CMMT from one comprehensive population-based
IBMFS registry and hypothesized that they have prognostic utility.

The Canadian Inherited Marrow Failure Registry

mined by fluorescence in situ hybridization, at a percentage higher
than the reference value.
The diagnostic criteria for pediatric MDS proposed by Hasle et
al. were used. Thus, at least two of the following criteria had to be
met: (i) sustained unexplained cytopenia, (ii) at least bilineage
prominent morphological myelodysplasia (>10% of the cells in
each lineage), (iii) acquired clonal cytogenetic abnormality in
hematopoietic cells, and (iv) 5%-29% blast cells.12 MDS cases also
could not have CMCA that are pathognomonic for AML, nor
could they have very rapid leukemic blast cell growth as indicated
by repeat bone marrow testing 2-3 weeks after diagnosis.
Information on all cases was reviewed centrally, and the diagnosis
of MDS could be modified based on these criteria. Clinical cases
of MDS that did not meet all diagnostic criteria were carefully
reviewed to determine whether the existing diagnostic criteria
needed to be modified.
AML was defined as ≥30% myeloid leukemic blasts in the bone
marrow or pathognomonic AML-type CMCA and very rapid
leukemic blast cell growth, as indicated in repeat bone marrow
testing 2-3 weeks after diagnosis.

The Canadian Inherited Marrow Failure Registry and its inclusion and exclusion criteria are described elsewhere,13,14 and are
summarized in the Online Supplementary Methods.

Classification of cases with clonal and malignant
myeloid transformation

Methods

Definition and diagnostic criteria
CMMT was defined as having bone marrow failure and at least
one of the following: (i) an isolated CMCA, (ii) MDS or (iii) AML.
CMCA was defined as the presence of at least two hematopoietic cells with the same cytogenetic abnormality detected by
metaphase cytogenetics or the presence of positive cells, as deter-

Grading or classification of CMMT was based on the CCC classification for pediatric MDS 2002.11 We made minor modifications
to the system that we published in 2002 (Table 1). First, we
changed the term ‘cytology’ to ‘cytopathology’ to reflect changes
found on bone marrow biopsy testing. Second, due to the natural
progression of MDS to AML, we added the category of AML secondary to MDS or chronic bone marrow failure syndrome. Third,

Table 1. The modified “category, cytopatology, cytogenetics” classification of childhood MDS.

Modified classification

2002 Classification

Comments

Category
1. Idiopathic (de novo)
2. Syndrome related
3. Therapy related

Category
1. Idiopathic (de-novo)
2. Syndrome related
3. Therapy related

Cytopathology
1. RC
2. RCRS
3. RCD
4. RCEB
5. AML secondary to MDS or
other chronic bone marrow failure

Cytology
1. RC
2. RCRS
3. RCD
4. RCEB

1. For a diagnosis of RC, IBMFS patients should have clear evidence
of clonality (e.g. CMCA) in addition to cytopenia, but should not
fulfill the diagnostic criteria for RCRS, RCD or RCEB as defined below.
Cases with hypercellular/normocellular RC as defined in Online
Supplementary Table S1 are also included.
2. RCRS is defined as having RC and >15% ringed sideroblasts in
the bone marrow (around >1/3 of the nuclear circumference).
Patients should not fulfill the criteria for RCD and RCEB.
3. RCD in the modified system specifically requires having RC and
prominent dysplasia (>10% of cells) in at least two cell lineages,
but no excess blasts
4. RCEB in both versions of the classification includes cases with 5-29%
blasts, and can include in addition either RC, RCRS or RCD

Cytogenetics/Genetics
1. Marrow cytogenetics genetic group
(to be specified)
2. Normal marrow cytogenetics/genetics
3. Unknown marrow cytogenetics/genetics

Cytogenetics
1. Marrow cytogenetic
abnormality (to be specified)
2. Normal marrow cytogenetics
3. Unknown marrow cytogenetics

Marrow cytogenetic/genetic abnormality refers to:
1. Acquired cytogenetic/genetic abnormality in the bone marrow
that is not constitutional (e.g. constitutional +21 in Down syndrome,
or +8 are not clonal marrow cytogenetic abnormalities).
2. The abnormality should appear in at least two cells
FISH analysis might be positive in cases in which regular cytogenetics
is negative. In such cases, the test type (FISH) has to be specified.

IBMFS: inherited bone marrow failure syndrome; FISH: fluorescent in situ hybridization; RC: refractory single/multilineage cytopenia without obvious dysplasia; RCD: refractory single/multilineage cytopenia with dysplasia; RCEB: refractory single/multilineage cytopenia with excess blasts (5–29%); RCRS: refractory single/multilineage cytopenia with ringed
sideroblasts.
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some degree of dysplasia is a feature of the IBMFS bone marrow
morphology and does not necessarily indicate malignancy,1,15,16
while single lineage dysplasia is an inherent feature of certain
inherited disorders. We, therefore, included only patients who had
prominent dysplasia (>10% of cells) in each lineage and in at least
two lineages to qualify for a diagnosis of refractory cytopenia with
dysplasia (RCD). Fourth, emerging genomics data can be incorporated in the future to characterize and understand IBMFS-associated CMMT; we, therefore, changed the heading ‘Cytogenetics’ to
“Cytogenetics/Genetics”.

Definition of disease progression
For patients who underwent HSCT, the duration of disease progression was calculated as the time from CMMT diagnosis to the
day before the transplant preparatory therapy was started. There
were no deaths that were unrelated to CMMT or transplant.
HSCT was applied at the discretion of the treating physician. The
indications for transplant included at least one of the following:
severe cytopenia, progressive cytopenia approaching severely low
counts and excess blasts.
Disease progression was defined by the development of one or
more of the following three criteria:
(i) one of the following cytopathological changes: (a) refractory
cytopenia (RC) or refractory cytopenia with ringed sideroblasts
(RCRS) to refractory cytopenia with dysplasia (RCD) or refractory
cytopenia with excess blasts (RCEB) or AML; (b) RCD to RCEB or
AML; (c) RCEB to AML;
(ii) one of the following cytogenetic changes: (a) new cytogenetic abnormality in patients with normal cytogenetics at baseline; (b)
new cytogenetic abnormality in those with a single cytogenetic
abnormality [such as del(20q) and trisomy 8, or i(7q) in
Shwachman-Diamond syndrome, SDS];
(iii) one of the following changes in the severity of bone marrow
failure: (a) single-lineage severe cytopenia to bilineage or trilineage
severe cytopenia; (b) bilineage severe cytopenia to trilineage
severe cytopenia. The various lineages were defined as severely
reduced if the platelet count was less than 20×109/L or transfusion
was required, if the hemoglobin concentration was less than 70
g/L or transfusion was required and if the absolute neutrophil
count was less than 0.5×109/L or granulocyte-colony stimulating
factor therapy was required.

Data analysis
Survival and risk were estimated by Kaplan-Meier analysis and
the Wilcoxon test was used to determine significant differences. P
values <0.05 were considered statistically significant. Some analyses (e.g. risk of CMMT) were stopped at the age of 18 years, due
to the possibility of referral bias of patients with CMMT who
were older than 18 years and were not treated at pediatric centers.
We did not include solid tumors in this study because of the small
number of patients with this complication. We chose IBMFS categories that had more than ten patients for our analyses. We also
only included categories that had more than three patients with
CMMT to assess the impact of category on progression and overall survival of patients with CMMT. We, therefore, included the
categories of Fanconi anemia (FA), SDS and unclassified-IBMFS.
We analyzed only cytopathological groups and cytogenetic groups
with more than three patients to determine how cytopathology
and cytogenetics affect progression and overall survival. The cytogenetic groups included were: (i) complex cytogenetics (≥3 cytogenetic abnormalities), (ii) del(7), del(7q) and deletion or translocation at areas 7q32-34, (iii) i(7q) and (iv) normal cytogenetics (constitutional abnormalities without CMCA were included).
Statistical analyses were performed using XLSTAT and Microsoft
Excel software.
haematologica | 2015; 100(5)

Results
Patients with inherited bone marrow failure syndromes
have a high risk of developing clonal and malignant
myeloid transformation
As of August 31st, 2011, 327 patients were enrolled in
the registry. Seven patients were excluded because of
missing information so a total of 320 patients were analyzed. The distribution of specific categories of IBMFS is
presented in Table 2. Forty-four patients met the criteria
of MDS or had frank AML. An additional patient with the
MDS/AML-predisposition syndrome (constitutional trisomy 8) had cytopenia and a hypercellular marrow without dysplasia, CMCA or excess blasts, and did not fit criteria for any other blood dyscrasia but MDS, and thus
was also included. This gave a crude CMMT prevalence
of 14.1% among IBMFS patients. Kaplan-Meier analysis
showed a risk of CMMT of 37% by the age of 18 years
(Figure 1A). The peak incidence of CMMT was between
the ages of 5-10 years (Online Supplementary Figure S1).
Forty-seven percent of patients were diagnosed with
CMMT at the time of diagnosis of their IBMFS. The
median age at diagnosis of IBMFS in those with CMMT
was 61.5 months (range, 0-376 months). The median age
at diagnosis of CMMT was 104 months (range, 8-756
months), compared to a median age of diagnosis of about
70 years in the general population of western countries.
The incidence of MDS in the United States in people aged
0-18 years is reported to be 1 per 1,000,000 per year and
the risk of developing AML before the age of 18 years is
8 per 1,000,000 per year.17-20 Given that the risk of developing CMMT in our study was 37% by the age of 18
years, the risk of CMMT (MDS and AML combined) during childhood among subjects with IBMFS is estimated to
be 2284-fold higher than the risk in the general population.
Twenty-five of the patients with CMMT (55.6%) were
males and 20 (44.4%) were females. Most patients (28/45,
62.2%) had physical malformations along with their
blood dyscrasia. Thirteen patients (28.9%) had physical
anomalies involving three or more non-hematologic systems (data not shown).
The 45 patients with CMMT were followed for a total
of 394 person-years with a median duration of 66 months
per patient (range, 1-423 months). Fifteen out of 45
patients (33.3%) progressed. Of the 30 patients who did
not progress, 14 required HSCT due to significant cytopenia or advanced MDS at presentation with CMMT; the
remaining 16 patients were followed for a total of 153 person-years with a median duration of 75 months per
patient (range, 1-309 months). The predicted risk of progression within 10 years of diagnosis with CMMT was
60% (Figure 1B).

Impact of clonal and malignant myeloid transformation
on survival
Overall mortality among the 45 patients with CMMT
was 33.3% (15/45), while overall mortality among the
non-CMMT group was 5.8% (16/275). Kaplan-Meier
analysis predicted that by the age of 18 years, the survival
rate in the CMMT group would be 56% compared to
92% in those without CMMT (P=0.02) by 18 years of age
(Figure 1C). The median survival after diagnosis of
CMMT was 32 months (range, 1-174 months). Causes of
635
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death in the CMMT group included: post-transplant complications in eight patients (4 therapy-related, 2 nonengraftment and 2 secondary graft failure), failure to
achieve remission (1 patient), and CMMT-related complications such as infections and bleeding complications (3
patients). The median age of death among patients with
CMMT was 12.8 years (range, 5.2-43.1 years) compared
to 7.1 years (range, 0.2-34 years) among those without
CMMT.

The impact of category of inherited bone marrow
failure syndrome on clonal and malignant myeloid
transformation risk and outcome
Among the whole group of patients in the registry,
CMMT was most common in patients with FA (14
patients), followed by SDS (9 patients) and unclassifiedIBMFS (13 patients) (Table 2). Other categories included
Kostmann/severe congenital neutropenia (K/SCN),
dyskeratosis congenita, and congenital amegakaryocytic
thrombocytopenia. There were two patients with constitutional mosaic trisomy 8, one with constitutional 4psyndrome1 and one with constitutional supernumerary
ring chromosome 1 among the patients with non-primary
IBMFS who had CMMT.
FA patients had the highest actuarial risk of 75% of
developing CMMT by 18 years of age. This was followed
by patients with dyskeratosis congenita, unclassified-

IBMFS, K/SCN and SDS with risks of about 25%, 24%,
24% and 20%, respectively, by 18 years of age (Figure 1DH). None of the patients with Diamond-Blackfan anemia
(DBA) developed CMMT. When we compared the three
categories with the largest numbers of patients, DBA, FA
and SDS, the difference in risk of developing CMMT by
18 years of age was statistically significant
(P=0.005)(Figure 1I). This difference was still significant
(P=0.02) when we compared DBA, FA, SDS, unclassifiedIBMFS, dyskeratosis congenita and K/SCN (data not
shown). The earliest age of onset of CMMT was 78
months in FA, 8 months in SDS, 201 months in dyskeratosis congenita, 57 months in K/SCN and 11 months in
unclassified-IBMFS.
The risk of progression within 10 years of diagnosis
with CMMT in patients with FA, SDS, and unclassifiedIBMFS was not significantly different between categories,
and was estimated to be 41%, 72% and 43%, respectively
(Figure 2A-E). The overall survival at 10 years from diagnosis with CMMT in FA, SDS and unclassified-IBMFS was
also not significantly different between categories, and
was estimated at 57%, 25%, and 91%, respectively
(Figure 2F-J).
We did not find a correlation between IBMFS category
and bone marrow failure severity, specific cytopathology,
or cytogenetics at presentation with CMMT (data not
shown).

Table 2. Categories of the IBMFS-associated cases of CMMT.

Number
of patients

Number of
patients
with CMMT

Median age at
diagnosis of
CMMT in months
(range)

Median duration of
follow-up of
patients with
CMMT in months
(range)

Median age of
patients without
CMMT at last
follow-up in
months (range)

Number progressed
to more advanced
CMMT

Number of
patients
deceased

DBA

52

NA

NA

1 (No CMMT)

41
40

K/SCN

13

0

6 (CMMT)
2 (No CMMT)
4 (CMMT)
1 (No CMMT)
1 (CMMT)

DC

13

58
(8-127)
239
(59-407)
179
(65-423)
32

5

SDS

103
(78-489)
205
(8-503)
167
(57- 756)
201

1

3 (No CMMT)

CAMT

2

80

98

118.5
(1-555)
68
(4-219)
113
(11-618)
159
(15-372)
64
(6-401)
20

NA

FA

0

0

UC-IBMFS

85
3

58
(11-174)
58

115
(1-662)
131

1

1 (CMMT)
8 (No CMMT)
2 (CMMT)

Const 4p-*
Const r(1)*
Other*

1
1
69

1
1
0

55
(11-200)
84.5
(45-124)
55
182
NA

4

Const +8*

0
(0%)
14
(31%)
9
(20%)
3
(23%)
1
(8%)
1
(50%)
13
(17%)
2

78
66
NA

0
0
NA

1 (CMMT)
0
1 (No CMMT)

Total

320

45

NA

NA

0
0
145
(2-690)
NA

15

15 (CMMT)
16 (No CMMT)

4

* Patients with non-primary IBMFS have hypo-productive cytopenia; however this complication is not a major component of their syndrome and does not occur in the majority of
patients.Therefore, patients with these disorders were not regularly enrolled in the Canadian Inherited Marrow Failure Registry, and epidemiological analysis could not be performed.
CAMT: congenital amegakaryocytic thrombocytopenia; CMMT: clonal and malignant myeloid transformation; Const: constitutional; DC: dyskeratosis congenita; DBA: DiamondBlackfan anemia; FA: Fanconi anemia; K/SCN: Kostmann/severe congenital neutropenia; NA: not applicable; SDS: Shwachman-Diamond syndrome; UC-IBMFS: unclassified inherited
bone marrow failure syndromes.
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Cytopathology of clonal and malignant myeloid
transformation associated with inherited bone
marrow failure syndromes and impact on outcome
The majority of patients with CMMT had RC (60%),
followed by RCEB (18%), RCD (9%), leukemia (AML, 7%
and B-precursor acute lymphoblastic leukemia, 2%) and
RCRS (4%) (Table 3).
The risk of CMMT progression to more advanced
CMMT tended to be higher in the RCEB group, being
70% within 3 years of the diagnosis of CMMT (Figure
3A). The rate of progression of RC was 37% and 65% at
3 and 10 years, respectively, after the diagnosis of CMMT

0.8
0.6
0.4
0.2

1

Probability of survival

Probability of no progression

Probability of no CMMT

1

0

0.8
0.6
0.4
0.2

0

50

100

150

200 250

P=0.02

0.6
CMMT

0.4
0.2

0

50 100 150 200 250
Age (months)

F DC

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

0.8

50
100 150
200
Time after diagnosis
of CMMT (months)

E SDS

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

No CMMT

1

0

0

50 100 150 200 250
Age (months)

D FA
Probability of no CMMT

C All disorders

B All disorders

A All disorders

0

(Figure 3B). Patients with RCRS and RCD had the lowest
rates of progression (Figure 3C,D).
The overall survival after diagnosis of CMMT was significantly different between the various cytopathologic
groups (Figure 3). Patients with RCEB and AML had the
poorest overall survival (P<0.0001). Importantly, patients
with RC did poorly with an overall survival of 37% at
long-term follow-up of 10 years.
There was no correlation between cytopathology and
bone marrow failure severity or specific cytogenetic
abnormalities at presentation with CMMT (data not
shown).

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0
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0
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200 250

Age (months)

H UC-IBMFS

Probability of no CMMT

G K/SCN
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

I DBA, SDS, FA
DBA

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

50
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200

250

1
SDS

0.8
0.6
0.4
P=0.005

0.2

FA

0
0
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200 250

0

50
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150

200 250

Age (months)
Figure 1. Characteristics and actuarial risk of clonal or malignant myeloid transformation (CMMT) among patients with IBMFS. (A) Actuarial
risk of CMMT was estimated by Kaplan-Meier analysis. Censoring was performed at last follow-up or at the time of hematopoietic stem cell
transplantation for patients who had undergone such a procedure. The figure represents risk with 95% confidence intervals. (B) Risk of progression to more advanced transformational stage among patients with CMMT. The figure represents risk with 95% confidence intervals. (C)
Overall survival analysis of patients with and without CMMT up to the age of 18 years. (D-I) Actuarial risk of CMMT among the common categories of inherited bone marrow failure syndromes: Fanconi anemia (FA), Shwachman-Diamond syndrome (SDS), dyskeratosis congenital (DC),
Kostmann/severe congenital neutropenia (K/SCN), unclassified-IBMFS (UC-IBMFS), and comparison between FA, SDS and DBA. The figures
represent risk with 95% confidence intervals.
haematologica | 2015; 100(5)
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Cytogenetics of clonal and malignant myeloid
transformation associated with inherited bone
marrow failure syndromes and impact on outcome
CMCA were present in 93% of the patients at presentation with CMMT (Table 4). One patient developed a
CMCA at follow-up. Monosomy 7, complex cytogenetics
and i(7q) were the most common CMCA, and were seen
in 36%, 21% and 11%, respectively, of the patients with
CMCA. These abnormalities were analyzed for their
prognostic values. Other cytogenetic groups were too
small for statistical analysis.
Rates of progression between the cytogenetic groups
were significantly different. Patients with monosomy 7
and complex cytogenetics had the highest risks of progression of 54% and 60%, respectively, at 5 years after the
diagnosis of CMMT (P=0.02; Figure 4A). There was no
statistically significant difference in overall survival
between the various cytogenetic groups (Figure 4B).
All patients with i(7q) were alive at last follow-up; however, this anomaly was associated with significant morbidity. Among the four patients with SDS and i(7q), one
patient suffered from severe multilineage cytopenia and
one from severe neutropenia at presentation. A third
patient with i(7q) developed an additional CMCA consisting of trisomy 8, as well as severe neutropenia at followup. One of the two patients with del(20q) developed
RCEB and subsequently AML 11 years after the first
appearance of this CMCA in the bone marrow.
There was no correlation between cytogenetics and the
severity of bone marrow failure or specific cytopathology
at presentation with CMMT (data not shown).

Discussion
The present study provides, for the first time, prognostic
data related to the category, cytopathology and cytogenetics of IBMFS-associated CMMT in a large group of patients
from one population-based registry. Our data showed an
estimated 2284-fold higher risk of CMMT in patients with
IBMFS than in the general population. Furthermore, the
development of CMMT in patients with IMBFS signaled a
high likelihood of malignant progression and significantly
increased mortality.
The risk of CMMT among the whole group of IBMFS has
never been studied. In our cohort of 320 patients, which
included patients diagnosed with the most common categories of IBMFS, the estimated risk of CMMT by the age of
18 years was 37%. It is known that the cumulative risk of
IBMFS-associated CMMT further increases in adulthood.
However, similar to all other studies that have been conducted on IBMFS, our registry may also suffer from referral
bias of patients with CMMT who are older than 18 years
of age and who are not treated at pediatric centers. We did
not, therefore, analyze certain factors (e.g. risk of CMMT)
for patients older than 18 years of age.
Few population-based data are available about the differential risk of developing CMMT among patients with various categories of IBMFS.21 Although the various IBMFS
share many clinical and morphological phenotypes, their
respective IBMFS genes play roles in several different biochemical pathways. It is, therefore, reasonable to hypothesize that mutations in different IBMFS genes may have different impacts on the malignant potential and behavior of
bone marrow cells. Our data indicate a significantly differ638

ent CMMT risk by the age of 18 years between DBA, FA
and SDS. CMMT was most common among FA patients,
who had a 75% risk by this time, which is much higher
than that described in other studies,5,8,22-24 and is even higher

Table 3. Cytopathology of IBMFS-associated CMMT at presentation.

Number
of patients

Refractory cytopenia
Refractory cytopenia with ringed
sideroblasts
Refractory cytopenia with dysplasia
Refractory cytopenia with excess blasts
Acute myeloid leukemia
Acute lymphocytic leukemia
Total

Number
Number
progressed to of patients
more advanced deceased (%)
CMMT (%)

27
2

10 (37)
0 (0)

5 (19)
1 (50)

4
8
3
1
45

0 (0)
4 (50)
1 (33)
NA
15 (33)

2 (50)
5 (62.5)
2 (67)
0 (0)
15 (33)

CMMT: clonal and malignant myeloid transformation.

Table 4. Cytogenetics of bone marrow samples at diagnosis of IBMFS-associated CMMT.

Number
Number
of patients progressed to
more advanced
CMMT
-7
Complex (> 3 cytogenetic abnormalities)
i(7)(q10)
-7, del(6)(q21)
-7 and del(7)(q22)
-7, inv(2)(p11.2;q13)c
t(7;21)(q34;q22)
t(14;16)(q11.1;p13.2)
t(3;12)(q26.2;p13)
del(2)(q33)
del(16)(q22)
del(20)(q11.2)
del(20)(q13.2)
der(15)t(1;15)(q12;q11)
der(4)t(4;8)(p16.3;p23.1)c
+i(l)(q10),+der(8)t(3;8)(q21;q23)
der(18)t(18 ;21)(p11.2;q22),
der(5)t(2;5)(p13;p15)
del(21)(q22) or r(21)(p11.1;q22),
+der(21)i(21)(q10) or del(21)(q22;q22)
+8c, +8, t(3;21)(q21;q22)
+X
+X, +8
-X and -21
Unknown
No clonal marrow cytogenetic
abnormalities
Total

Number
of patients
deceased

11
6
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1

3
3
1
0
1
0
1
1
0
0
0
1
0
1
0
0
1

0
3
0
0
1
1
0
0
0
1
0
1
0
1
1
1
0

1

1

1

1
1
1
1
1
3

1
0
0
0
NA
0

1
0
0
0
1
2

45

15

15

CMMT: clonal and malignant myeloid transformation; NA, not applicable.
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than that reported in studies in which patients with isolated
clones were included.22 This may reflect our comprehensive
registry inclusion criteria and meticulous collection of data
on all bone marrow testing. SDS patients had a high risk of
20% of developing CMMT by the age of 18 years. This
information provides the rationale for routine leukemia surveillance in children with FA and SDS.25 In contrast, no
patient with DBA developed CMMT in our cohort, suggesting that cancer surveillance with annual bone marrow
testing during childhood is not indicated in DBA. The need
for surveillance for patients with DBA after the age of 18
years is not yet clear. The development of CMMT in children with K/SCN and dyskeratosis congenita is consistent
with the literature and reinforces the need for surveillance
in these populations.
Patients with unclassified-IBMFS manifest bone marrow
failure and heterogeneous clinical and genetic characteristics. We found a substantially, and previously unreported,
high risk of CMMT (24%) before 18 years of age in this
population. This underlies the critical need to initiate cancer
surveillance even when the precise syndrome and genetic
group is unknown. Although the majority of patients with
unclassified-IBMFS underwent extensive genetic testing
that was negative, not all of them were tested for mutations
in all known IBMFS genes. Some of the unclassified cases
with CMMT in this group might, therefore, have mutations
in genes such as RUNX1 and GATA2. Importantly, patients
who present with idiopathic MDS are often not comprehensively tested for mutations in IBMFS. Hence, a proportion of the IBMFS patients who have neither a positive family history nor physical malformations and present with
idiopathic MDS, would not be captured by our registry.
The magnitude of this population of patients remains to be
determined.
Our results indicate for the first time that CMMT is a progressive risk and significantly affects survival, which indicates a major need to develop strategies for prevention and
early detection. It is noteworthy that the high rate of progression was identified at a median follow-up of 66
months, and that the prognosis may be even worse with
longer follow-up. The impact of underlying category of
IBMFS on the outcome of CMMT is unknown. The results
of our study indicate no differences in disease progression
and survival between patients with the common IBMFS
after they develop CMMT. This might be due to the small
numbers of patients in each category. Alternatively, it may
be that the long-term outcome is substantially affected
regardless of the specific IBMFS category. Interestingly, the
pattern of progression and mortality was different between
FA and SDS patients (Figure 3). FA patients had initially high
progression and mortality rates and then a plateau, whereas
SDS patients had a persistent risk of progression and drop
in survival over time. The early and fast drop in survival in
FA patients is likely due to early intervention with HSCT
due to concomitant signs of severe cytopenia. Indeed, 11 of
14 patients with FA and CMMT underwent HSCT and the
majority survived. Only one patient with SDS and CMMT
underwent HSCT. The data therefore likely reflect the natural history of SDS patients with CMMT, and although past
studies suggested that progression of these patients from
CMCA to advanced MDS and AML might be slow,1,26,27 our
data demonstrate that the risk of progression and mortality
continue without a plateau from the time the CMMT is
diagnosed. Although the number of SDS patients with
CMMT is small, these results indicate a crucial need for furhaematologica | 2015; 100(5)

ther confirmation of these findings and for research into
whether early intervention with HSCT in certain SDS
patients could improve outcome.
In our study, RC was the most common cytopathology in
IBMFS-associated CMMT.12,28 Patients with RC fared significantly better than those with RCEB with respect to progression and survival. The predicted risk of progression in
those with RCEB was high early after diagnosis, in line with
the findings of previous studies of MDS.29,30 Surprisingly, the
risk of progression in patients with RC persisted and continued to increase over time with no apparent plateau.
Clearly, the impact of early intervention with HSCT on
overall survival in this group should be studied.
In contrast to de novo MDS, in which 30-50% of patients
have a CMCA,31-33 CMCA were seen in 93% of our patients
with IBMFS-associated CMMT at the time of presentation.
Based on the International Prognostic Scoring System for
adult MDS, monosomy 7 and complex cytogenetics (≥3
chromosomal abnormalities) are classified as poor prognostic features.34 Monosomy 7 occurred in one-third of our
patients and was the most common CMCA, as in children
and adolescents with de novo MDS.7 The predicted risk of
progression and estimated survival of patients with monosomy 7 at 5 years after diagnosis of CMMT were 54% and
85%, respectively. Over one third of the patients with
monosomy 7 did not receive a transplant and were alive at
last follow-up. These results suggest a novel concept that
HSCT may not be automatically necessary for all patients
with monosomy 7, but only offered to those who have
either significant or progressive cytopenia or excess blasts.
Discovery of co-existing genetic alterations and definition
of their prognostic significance will help to refine the transplant indications in this group. Patients with complex cytogenetics had a poor outcome in our study with a 60% predicted risk of progression as early as 1 year after the diagnosis of CMMT, and a 50% predicted overall survival at 5
years. This is similar to reports of poor outcome in patients
with de novo MDS and complex cytogenetics.31,34,35
Isochromosome 7q and del(20q) can be seen for many
years in the bone marrow from patients with stable SDS
and can even become periodically undetectable.1,36-38
Surprisingly, in the present study, three out of four patients
with i(7q) and SDS had significant complications at presentation or at last follow-up. In addition, one of the two
patients with del(20q) developed RCEB and AML 11 years
after the first appearance of this CMCA. These data may
suggest that newly appearing clones with i(7q) and del(20q)
signal a slowly progressive bone marrow dyscrasia that will
eventually require treatment. Larger cohorts with longer
follow-up are needed to determine the true impact of these
cytogenetic abnormalities on progression to more severe
bone marrow failure and/or leukemia.
Two classifications of pediatric MDS have been proposed
due to increasing awareness of the biological and clinical differences between pediatric and adult MDS. In addition to
the 2002 CCC pediatric MDS classification, a World Health
Organization (WHO) pediatric MDS classification was
developed in 2003 and revised in 2008.12,39-41 This classification focuses on MDS cytopathology and includes three
classes: RC of childhood (RCC), RAEB (myeloblasts of 519%) and RAEB in transformation (RAEB-t, myeloblasts of
20-29%). RCRS was omitted from the pediatric WHO MDS
classification due to its rarity in childhood. RCD was combined with RCC due to yet unclear differences from RCC.
The pediatric WHO classification has several limitations.
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First, although 40% of children with MDS have an underlying IBMFS,11 the classification is mainly based on experience
from de novo MDS and designed for this MDS category. The
application of this classification to IBMFS has never been
studied. Second, the omission of RCRS from the pediatric
WHO classification did not take into account that despite its
rarity, this cytopathology exists in children, as evidenced by
this series and other reports in the literature.42 Had we used
the pediatric WHO MDS classification we could not have
categorized either of our cases of RCRS. Third, the significance of RCD has not been systematically and thoroughly

Probability of no progression

A FA

studied in IBMFS. Although our numbers are small, there is
a suggestion that this category carries a different risk of progression and survival than RC (Online Supplementary Figures
S2 and S3). Hence, further studies are required before RCD
is omitted as a separate entity from the pediatric MDS classifications. The pediatric CCC classification was designed to
include all categories of MDS (de novo, therapy-related and
syndrome-associated). To our knowledge the present study
tests for the first time the prognostic significance of a pediatric MDS classification in a large cohort of patients with
IBMFS-associated MDS or CMMT.
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Figure 2. Actuarial risk of progression and survival of clonal
or malignant myeloid transformation (CMMT) among the various categories of inherited
bone marrow failure syndromes. (A) Fanconi anemia
(FA), (B) Shwachman-Diamond
syndrome
(SDS),
(C)
Kostmann/severe congenital
neutropenia (K/SCN), (D)
Unclassified-IBMFS
(UCIBMFS). (E) Comparative analysis between FA, SDS and UCIBMFS. The figures represent
risk with 95% confidence intervals. (F) Fanconi anemia (FA),
(G) Shwachman-Diamond syndrome
(SDS),
(C)
Kostmann/severe congenital
neutropenia (K/SCN), (H)
Unclassified-IBMFS
(UCIBMFS), (I) Comparative analysis between FA, SDS, UCIBMFS all groups with more
than three patients with
CMMT, (J) Comparative analysis of three categories (without
K/SCN). The figures represent
risk with 95% confidence intervals.
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One of the cases in the present series did not fit the
MDS diagnostic criteria proposed by Hasle et al.12
However, the patient clearly had MDS, since he had an
MDS/AML predisposition syndrome (constitutional trisomy 8), progressive cytopenia and a hypercellular bone
marrow. He did not have prominent dysplasia, ringed
sideroblasts, excess blasts, cytogenetic abnormalities or
indication of any other dietary, metabolic or infectious disorder that could account for the blood dyscrasia. We propose modifying the diagnostic criteria of pediatric MDS
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(Online Supplementary Table S1) and including cytopenia
with hypercellular bone marrow that cannot be explained
by causes other than MDS.
The data in the present study help to define the impact of
category, cytopathology and bone marrow cytogenetic
abnormalities on the characteristics and prognosis of
IBMFS-associated CMMT. These components of the CCC
classification simplify the wide assortment of variables that
constitute pediatric MDS and CMMT into one scheme, and
hence can be used clinically to describe the disease at pres-
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Figure 3. Impact of cytopathology on outcome of patients with clonal or malignant myeloid transformation (CMMT). Actuarial risk of progression after CMMT diagnosis among the various classes of cytopathology at presentation: (A) refractory cytopenia (RC), (B) refractory cytopenia
with excess blasts (RCEB), (C) refractory cytopenia with ringed sideroblasts (RCRS), (D) refractory cytopenia with dysplasia (RCD). Comparative
analysis between groups was not significant (P=0.18). Overall survival after CMMT diagnosis among the various classes of cytopathology at
presentation: (E) refractory cytopenia (RC), (F) refractory cytopenia with excess blasts (RCEB), (G) refractory cytopenia with ringed sideroblasts
(RCRS), (H) refractory cytopenia with dysplasia (RCD), (I) acute myeloid leukemia (AML). Comparative analysis showed a statistically significant difference (P<0.0001).
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Figure 4. Impact of cytogenetics on outcome of patients with clonal or malignant myeloid transformation (CMMT). (A) Actuarial risk of progression of CMMT; (B) overall survival of patients with CMMT.
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entation and follow-up. Due to the rarity of the disorders,
the numbers in certain categories, cytopathologies and
cytogenetic groups were small; thus, enrolling further
patients and longer follow-up will be important for replicating the data and defining additional cytogenetic and genetic
variables as risk factors. Emerging genomic data can be
incorporated and be used to further characterize and understand IBMFS-associated CMMT.
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